Mark A. Dickson
YOU?
Author Swipe
View article: P108 Rapidly progressive interstitial lung disease and unmasking anti-EJ antisynthetase syndrome: a case for early multidisciplinary recognition
P108 Rapidly progressive interstitial lung disease and unmasking anti-EJ antisynthetase syndrome: a case for early multidisciplinary recognition Open
Introduction Antisynthetase Syndrome (ASS) is a rare autoimmune condition associated with interstitial lung disease (ILD), arthritis, and myositis, characterised by anti-aminoacyl-tRNA synthetase antibodies. ILD may be the first or only ma…
View article: Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor Open
Representativeness of Study Participants
View article: Data from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Data from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor Open
Purpose:This study investigated factors that affected ctDNA detection and ctDNA as a molecular biomarker in a phase II trial of imatinib and binimetinib in newly diagnosed advanced gastrointestinal stromal tumor, including patients exposed…
View article: High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy Open
Background Response to immune checkpoint inhibition (ICI) in sarcomas is overall low and heterogeneous. Understanding determinants of ICI outcomes may improve efficacy and patient selection. Thus, we investigated whether the expression of …
View article: Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma Open
Background Objective responses to immune checkpoint inhibitors (ICI) in leiomyosarcoma (LMS) are rare. Response rates may be increased by combination with other drugs known to promote immune infiltration, such as poly(ADP-ribose) polymeras…
View article: ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results Open
PURPOSE We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS Preclinical work identified ACR-368 activity in DSRCT, and a ph…
View article: Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022
Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022 Open
Background Kaposi sarcoma (KS) is a vascular tumor caused by human herpesvirus 8, also known as Kaposi sarcoma herpesvirus. There are 4 distinct subtypes: classic, endemic, iatrogenic, and epidemic (HIV-associated). A fifth subtype is incr…
View article: Data from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Data from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C Open
Purpose:Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of…
View article: Supplementary Table S2 from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Supplementary Table S2 from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C Open
Representativeness of Study Participants
View article: Supplementary Table S1 from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Supplementary Table S1 from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C Open
Patient Characteristics of the Eligible and Treated Population (n=38)
View article: Supplementary Figure S1 from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Supplementary Figure S1 from Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C Open
Supplementary Figure 1: Progression Free and Overall Survival in the Eligible and Treated Population (n=38) Kaplan Meier plots for progression free (A) and overall (B) survival in the eligible and treated population (n=38)
View article: Supplementary Figure S2 from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Supplementary Figure S2 from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma Open
Supplementary Figure 2. Overall survival by (A) cohort and (B) histology.
View article: Supplementary Figure S1 from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Supplementary Figure S1 from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma Open
Supplementary Figure 1. Progression-free survival by histology.
View article: Supplementary Table S1 from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Supplementary Table S1 from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma Open
Supplementary Table 1: Representativeness of study participants
View article: Data from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Data from Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma Open
Purpose:Survival of patients with metastatic sarcoma remains poor, and there is a pressing need for new therapies. Most sarcoma subtypes are not responsive to immune checkpoint inhibition alone. Lenvatinib, a multireceptor tyrosine kinase …
View article: Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C Open
Purpose: Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C o…
View article: Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma Open
Purpose: Survival of patients with metastatic sarcoma remains poor, and there is a pressing need for new therapies. Most sarcoma subtypes are not responsive to immune checkpoint inhibition alone. Lenvatinib, a multireceptor tyrosine kinase…
View article: Supplementary Data 1 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Supplementary Data 1 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Representativeness of study participants.
View article: Supplementary Data 1 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Supplementary Data 1 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Representativeness of study participants.
View article: Supplementary Data 3 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Supplementary Data 3 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Normalized Kynurenine Concentrate Over Time
View article: Supplementary Data 2 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Supplementary Data 2 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Normalized Tryptophan Concentrate Over Time
View article: Supplementary Data 3 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Supplementary Data 3 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Normalized Kynurenine Concentrate Over Time
View article: Supplementary Data 2 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Supplementary Data 2 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Normalized Tryptophan Concentrate Over Time
View article: Data from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Data from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma Open
Purpose: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined ep…
View article: Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Abemaciclib induced changes in CD8+ TILs in individual patients
View article: Supplementary Figure S7 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S7 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
ANGPTL4 is the most widely expressed and highly enriched transcript in treated cells compared to untreated cells